INFOGRAPHIC: High-Risk HR+, HER2- EBC: Carryover Effect of Oral Endocrine Therapy
As healthcare providers, it is important to understand the carry over effect of endocrine therapy for patients with HR+ EBC to develop an individualized treatment plan.
Date of Last Review: February 22, 2024
Please rate your satisfaction with the content on the following statements:
Very Dissatisfied
Dissatisfied
Neutral
Satisfied
Very Satisfied
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice
Please rate your satisfaction with the content on the following statements:
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice